Summary
48.28 0.84(1.77%)10/04/2024
Azenta Inc (AZTA)
Azenta Inc (AZTA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.77 | 5.09 | -2.80 | -15.25 | 12.14 | 21.35 | 0.00 | 453.51 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 48.28 | |
| Open | 47.86 | |
| High | 48.63 | |
| Low | 47.77 | |
| Volume | 183,710 | |
| Change | 0.84 | |
| Change % | 1.77 | |
| Avg Volume (20 Days) | 419,165 | |
| Volume/Avg Volume (20 Days) Ratio | 0.44 | |
| 52 Week Range | 36.01 - 69.16 | |
| Price vs 52 Week High | -30.19% | |
| Price vs 52 Week Low | 34.07% | |
| Range | -0.93 | |
| Gap Up/Down | 0.29 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2,406 | |
| EBIDTA | 68,693,000 | |
| PE Ratio | 64.3367 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 138.83 | |
| Book Value | 18.0910 | |
| Earnings Per Share | 1.4850 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | 1.4850 | |
| Revenues | ||
| Profit Marging | 0.2156 | |
| Operating Marging (TTM) | 0.0065 | |
| Return on asset (TTM) | 0.0012 | |
| Return on equity (TTM) | -0.0227 | |
| Revenue TTM | 513,703,008 | |
| Revenue per share TTM | 6.9210 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | -0.2420 | |
| Gross Profit (TTM) | 243,809,000 | |
| Dividends | ||
| Dividend Share | 0.4000 | |
| Dividend Yield | 0.0041 | |
| Valuations | ||
| Trailing PE | 64.3367 | |
| Forward PE | 33.4448 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.7505 | |
| Revenue Enterprise Value | 14.5776 | |
| EBITDA Enterprise Value | 406.9656 | |
| Shares | ||
| Shares Outstanding | 74,347,104 | |
| Shares Float | 71,920,703 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 1.62 | |
| Institutions (%) | 95.66 | |
09/04 08:00 EST - prnewswire.com
AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO
Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass. , Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) ("Azenta" or "the Company"), today announced that John P.
AZENTA ANNOUNCES APPOINTMENT OF JOHN P. MAROTTA AS CEO
Succeeds Dr. Stephen Schwartz Following 14-Year Tenure BURLINGTON, Mass. , Sept. 4, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) ("Azenta" or "the Company"), today announced that John P.
08/12 16:05 EST - prnewswire.com
GENEWIZ from Azenta Life Sciences Celebrates 25 Years of Advancing Scientific Discoveries at GENEWIZ Week Event
BURLINGTON, Mass. , Aug. 12, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that GENEWIZ Multiomics and Synthesis Solutions from Azenta Life Sciences will be hosting its 25th anniversary and the launch of its annual GENEWIZ Week event on September 16 - 20.
GENEWIZ from Azenta Life Sciences Celebrates 25 Years of Advancing Scientific Discoveries at GENEWIZ Week Event
BURLINGTON, Mass. , Aug. 12, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that GENEWIZ Multiomics and Synthesis Solutions from Azenta Life Sciences will be hosting its 25th anniversary and the launch of its annual GENEWIZ Week event on September 16 - 20.
08/06 19:40 EST - seekingalpha.com
Azenta, Inc. (AZTA) Q3 2024 Earnings Call Transcript
Azenta, Inc. (NASDAQ:AZTA ) Q3 2024 Results Conference Call August 6, 2024 4:30 PM ET Company Participants Yvonne Perron - Vice President, FP&A and Investor Relations Steve Schwartz - President and Chief Executive Officer Herman Cueto - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Sophia Knopp - Evercore ISI Noah Lewis - Raymond James Matt Stanton - Jefferies Lucas Baranowski - KeyBanc Capital Operator Greetings, and welcome to the Azenta Third Quarter 2024 Financial Results. [Operator Instructions].
Azenta, Inc. (AZTA) Q3 2024 Earnings Call Transcript
Azenta, Inc. (NASDAQ:AZTA ) Q3 2024 Results Conference Call August 6, 2024 4:30 PM ET Company Participants Yvonne Perron - Vice President, FP&A and Investor Relations Steve Schwartz - President and Chief Executive Officer Herman Cueto - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Sophia Knopp - Evercore ISI Noah Lewis - Raymond James Matt Stanton - Jefferies Lucas Baranowski - KeyBanc Capital Operator Greetings, and welcome to the Azenta Third Quarter 2024 Financial Results. [Operator Instructions].
08/06 19:15 EST - zacks.com
Azenta (AZTA) Q3 Earnings and Revenues Top Estimates
Azenta (AZTA) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.13 per share a year ago.
Azenta (AZTA) Q3 Earnings and Revenues Top Estimates
Azenta (AZTA) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.13 per share a year ago.
08/06 16:05 EST - prnewswire.com
Azenta Reports Third Quarter Results for Fiscal 2024, Ended June 30, 2024
BURLINGTON, Mass. , Aug. 6, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2024.
Azenta Reports Third Quarter Results for Fiscal 2024, Ended June 30, 2024
BURLINGTON, Mass. , Aug. 6, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2024.
08/05 16:05 EST - prnewswire.com
Azenta to Participate in 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
BURLINGTON, Mass. , Aug. 5, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference, on Monday, August 12, 2024.
Azenta to Participate in 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
BURLINGTON, Mass. , Aug. 5, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference, on Monday, August 12, 2024.
07/30 11:07 EST - zacks.com
Analysts Estimate Azenta (AZTA) to Report a Decline in Earnings: What to Look Out for
Brooks (AZTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Azenta (AZTA) to Report a Decline in Earnings: What to Look Out for
Brooks (AZTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/30 10:01 EST - zacks.com
Is the Options Market Predicting a Spike in Azenta (AZTA) Stock?
Investors need to pay close attention to Azenta (AZTA) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Azenta (AZTA) Stock?
Investors need to pay close attention to Azenta (AZTA) stock based on the movements in the options market lately.
07/24 16:05 EST - prnewswire.com
Azenta Announces Fiscal 2024 Third Quarter Earnings Conference Call and Webcast
BURLINGTON, Mass. , July 24, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2024 earnings which ended on June 30, 2024, on Tuesday, August 6, 2024, after the market closes.
Azenta Announces Fiscal 2024 Third Quarter Earnings Conference Call and Webcast
BURLINGTON, Mass. , July 24, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2024 earnings which ended on June 30, 2024, on Tuesday, August 6, 2024, after the market closes.
07/22 16:05 EST - prnewswire.com
FinnGen Selects Azenta to Propel Personalized Medicine for Population Health Study
Azenta will provide proteomics technology profiling on up to 20,000 individuals. BURLINGTON, Mass.
FinnGen Selects Azenta to Propel Personalized Medicine for Population Health Study
Azenta will provide proteomics technology profiling on up to 20,000 individuals. BURLINGTON, Mass.
07/16 06:10 EST - zacks.com
New Strong Buy Stocks for July 16th
BTG, APOG, AZTA, AFYA and KGC have been added to the Zacks Rank #1 (Strong Buy) List on July 16, 2024.
New Strong Buy Stocks for July 16th
BTG, APOG, AZTA, AFYA and KGC have been added to the Zacks Rank #1 (Strong Buy) List on July 16, 2024.
06/04 16:05 EST - prnewswire.com
Azenta Announces Collaboration with the Crohn's & Colitis Foundation to Support its Crohn's Disease and Ulcerative Colitis Clinical Research
Azenta has been Selected by the Crohn's & Colitis Foundation as its Sample Management Services Provider for its Inflammatory Bowel Disease (IBD) CAPTURE and SIRQC Clinical Registries BURLINGTON, Mass. , June 4, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced it has been selected by the Crohn's & Colitis Foundation (the "Foundation") as its sample management services provider for two of its large-scale prospective research cohorts, CAPTURE IBD and IBD SIRQC, which investigate pediatric and surgical care for Crohn's disease and ulcerative colitis.
Azenta Announces Collaboration with the Crohn's & Colitis Foundation to Support its Crohn's Disease and Ulcerative Colitis Clinical Research
Azenta has been Selected by the Crohn's & Colitis Foundation as its Sample Management Services Provider for its Inflammatory Bowel Disease (IBD) CAPTURE and SIRQC Clinical Registries BURLINGTON, Mass. , June 4, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced it has been selected by the Crohn's & Colitis Foundation (the "Foundation") as its sample management services provider for two of its large-scale prospective research cohorts, CAPTURE IBD and IBD SIRQC, which investigate pediatric and surgical care for Crohn's disease and ulcerative colitis.
05/23 16:05 EST - prnewswire.com
Azenta to Participate in the Jefferies Global Healthcare Conference
BURLINGTON, Mass. , May 23, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Jefferies Global Healthcare Conference in New York, NY, on Wednesday, June 5, 2024, which includes a presentation beginning at 11:00 am ET.
Azenta to Participate in the Jefferies Global Healthcare Conference
BURLINGTON, Mass. , May 23, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Jefferies Global Healthcare Conference in New York, NY, on Wednesday, June 5, 2024, which includes a presentation beginning at 11:00 am ET.
05/20 07:34 EST - https://www.defenseworld.net
Azenta (NASDAQ:AZTA) Issues FY 2024 Earnings Guidance
Azenta (NASDAQ:AZTA – Get Free Report) issued an update on its FY 2024 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 0.270-0.370 for the period, compared to the consensus estimate of 0.260. The company issued revenue guidance of $659.0 million-$671.0 million, compared to the consensus revenue estimate of $703.8 million. Azenta Stock Performance Shares of NASDAQ:AZTA opened at $50.87 on Monday. The company has a market capitalization of $2.74 billion, a P/E ratio of -18.77 and a beta of 1.51. The company’s 50-day moving average is $55.67 and its 200 day moving average is $59.53. Azenta has a fifty-two week low of $40.41 and a fifty-two week high of $69.16. Azenta (NASDAQ:AZTA – Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03. The business had revenue of $159.13 million during the quarter, compared to analyst estimates of $159.89 million. Azenta had a positive return on equity of 0.81% and a negative net margin of 23.12%. Azenta’s revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.06) earnings per share. As a group, research analysts predict that Azenta will post 0.29 earnings per share for the current year. Analyst Ratings Changes A number of research analysts have commented on the stock. Stephens reiterated an equal weight rating and set a $70.00 price target on shares of Azenta in a research report on Thursday, February 8th. B. Riley increased their target price on shares of Azenta from $61.00 to $79.00 and gave the company a buy rating in a report on Thursday, February 1st. Evercore ISI lowered their price target on shares of Azenta from $64.00 to $60.00 and set an in-line rating for the company in a research note on Thursday, April 4th. Needham & Company LLC reduced their price objective on Azenta from $75.00 to $69.00 and set a buy rating on the stock in a research note on Thursday, May 9th. Finally, Jefferies Financial Group began coverage on Azenta in a research note on Thursday, April 4th. They issued a hold rating and a $64.00 target price for the company. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Azenta currently has a consensus rating of Hold and a consensus price target of $68.40. Get Our Latest Report on Azenta About Azenta (Get Free Report) Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.
Azenta (NASDAQ:AZTA) Issues FY 2024 Earnings Guidance
Azenta (NASDAQ:AZTA – Get Free Report) issued an update on its FY 2024 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 0.270-0.370 for the period, compared to the consensus estimate of 0.260. The company issued revenue guidance of $659.0 million-$671.0 million, compared to the consensus revenue estimate of $703.8 million. Azenta Stock Performance Shares of NASDAQ:AZTA opened at $50.87 on Monday. The company has a market capitalization of $2.74 billion, a P/E ratio of -18.77 and a beta of 1.51. The company’s 50-day moving average is $55.67 and its 200 day moving average is $59.53. Azenta has a fifty-two week low of $40.41 and a fifty-two week high of $69.16. Azenta (NASDAQ:AZTA – Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03. The business had revenue of $159.13 million during the quarter, compared to analyst estimates of $159.89 million. Azenta had a positive return on equity of 0.81% and a negative net margin of 23.12%. Azenta’s revenue was up 7.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.06) earnings per share. As a group, research analysts predict that Azenta will post 0.29 earnings per share for the current year. Analyst Ratings Changes A number of research analysts have commented on the stock. Stephens reiterated an equal weight rating and set a $70.00 price target on shares of Azenta in a research report on Thursday, February 8th. B. Riley increased their target price on shares of Azenta from $61.00 to $79.00 and gave the company a buy rating in a report on Thursday, February 1st. Evercore ISI lowered their price target on shares of Azenta from $64.00 to $60.00 and set an in-line rating for the company in a research note on Thursday, April 4th. Needham & Company LLC reduced their price objective on Azenta from $75.00 to $69.00 and set a buy rating on the stock in a research note on Thursday, May 9th. Finally, Jefferies Financial Group began coverage on Azenta in a research note on Thursday, April 4th. They issued a hold rating and a $64.00 target price for the company. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Azenta currently has a consensus rating of Hold and a consensus price target of $68.40. Get Our Latest Report on Azenta About Azenta (Get Free Report) Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.
05/14 06:34 EST - investorplace.com
Stock Market Crash Warning: Don't Get Caught Holding These 3 Robotics Stocks
Robotics and automation go hand in hand. Inflationary pressures have been plaguing both consumers and business owners.
Stock Market Crash Warning: Don't Get Caught Holding These 3 Robotics Stocks
Robotics and automation go hand in hand. Inflationary pressures have been plaguing both consumers and business owners.
05/13 16:46 EST - prnewswire.com
Azenta Opens the Doors to Its New Genomics Laboratory in Oxford, UK
BURLINGTON, Mass. , May 13, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the grand opening of the new Genomics Laboratory in Oxford, UK, expanding its global reach of GENEWIZ Multiomics & Synthesis Solutions further in the UK market.
Azenta Opens the Doors to Its New Genomics Laboratory in Oxford, UK
BURLINGTON, Mass. , May 13, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the grand opening of the new Genomics Laboratory in Oxford, UK, expanding its global reach of GENEWIZ Multiomics & Synthesis Solutions further in the UK market.
05/08 19:54 EST - seekingalpha.com
Azenta, Inc. (AZTA) Q2 2024 Earnings Call Transcript
Azenta, Inc. (NASDAQ:AZTA ) Q2 2024 Results Conference Call May 8, 2024 4:30 PM ET Company Participants Yvonne Perron - Vice President, FP&A and Investor Relations Steve Schwartz - President and Chief Executive Officer Herman Cueto - Chief Financial Officer Conference Call Participants David Saxon - Needham Hannah Hefley - Stephens Vijay Kumar - Evercore ISI Yuan Zhi - B. Riley Matt Stanton - Jefferies Operator Greetings, and welcome to the Azenta Second Quarter 2024 Financial Results.
Azenta, Inc. (AZTA) Q2 2024 Earnings Call Transcript
Azenta, Inc. (NASDAQ:AZTA ) Q2 2024 Results Conference Call May 8, 2024 4:30 PM ET Company Participants Yvonne Perron - Vice President, FP&A and Investor Relations Steve Schwartz - President and Chief Executive Officer Herman Cueto - Chief Financial Officer Conference Call Participants David Saxon - Needham Hannah Hefley - Stephens Vijay Kumar - Evercore ISI Yuan Zhi - B. Riley Matt Stanton - Jefferies Operator Greetings, and welcome to the Azenta Second Quarter 2024 Financial Results.
05/08 16:06 EST - prnewswire.com
Azenta Announces CEO Succession Plan
CEO Dr. Stephen Schwartz to Retire; Search Underway to Identify Successor BURLINGTON, Mass. , May 8, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a CEO succession plan, under which CEO and Board Director Dr. Stephen Schwartz will be retiring from Azenta after more than 14 years of service.
Azenta Announces CEO Succession Plan
CEO Dr. Stephen Schwartz to Retire; Search Underway to Identify Successor BURLINGTON, Mass. , May 8, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a CEO succession plan, under which CEO and Board Director Dr. Stephen Schwartz will be retiring from Azenta after more than 14 years of service.
05/08 16:05 EST - prnewswire.com
Azenta Reports Second Quarter Results for Fiscal 2024, Ended March 31, 2024
BURLINGTON, Mass. , May 8, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2024.
Azenta Reports Second Quarter Results for Fiscal 2024, Ended March 31, 2024
BURLINGTON, Mass. , May 8, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2024.
05/01 16:05 EST - prnewswire.com
Azenta Announces Fiscal 2024 Second Quarter Earnings Conference Call and Webcast
BURLINGTON, Mass., May 1, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal second quarter 2024 earnings which ended on March 31, 2024, on Wednesday, May 8, 2024, after the market closes.
Azenta Announces Fiscal 2024 Second Quarter Earnings Conference Call and Webcast
BURLINGTON, Mass., May 1, 2024 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal second quarter 2024 earnings which ended on March 31, 2024, on Wednesday, May 8, 2024, after the market closes.